Drug Type Small molecule drug |
Synonyms Aramisuto, Arnuity Ellipta, Fluticasone furoate (JAN/USAN/INN) + [14] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (16 Jun 2000), |
Regulation- |
Molecular FormulaC27H29F3O6S |
InChIKeyXTULMSXFIHGYFS-VLSRWLAYSA-N |
CAS Registry397864-44-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06315 | Fluticasone furoate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | United States | 20 Aug 2014 | |
Pulmonary Disease, Chronic Obstructive | Australia | 17 Apr 2014 | |
Rhinitis, Allergic, Perennial | Canada | 22 Oct 2007 | |
Rhinitis, Allergic, Seasonal | Canada | 22 Oct 2007 | |
Rhinitis, Allergic | China | 16 Jun 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | Phase 3 | United States | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | China | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Japan | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Argentina | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Australia | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Austria | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Belarus | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Belgium | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Bosnia and Herzegovina | 25 Jan 2011 | |
Cardiovascular Diseases | Phase 3 | Bulgaria | 25 Jan 2011 |
Not Applicable | Rhinitis, Allergic, Perennial Maintenance | 87 | Fluticasone propionate/azelastine (FP/Aze 50/137 μg each nostril twice daily) | zffzylnwak(ekfmhbmzle): mean difference = 1.26 (95% CI, 0.59 - 1.93), P-Value = <0.001 | Positive | 23 Feb 2024 | |
Fluticasone furoate (FF 55 μg each nostril once daily) | |||||||
Not Applicable | - | hbkcfphzzw(hoaaactvzt) = Similar proportions of participants experienced ≥1 on-treatment adverse event (AE) in both populations (5-17 year-olds: n=181/454 [40%] receiving FF/VI versus n=163/448 [36%] receiving FF; 5-11 year-olds: n=133/337 [39%] receiving FF/VI versus n=122/336 [36%] receiving FF) botlzqwifb (tcyeufvkus ) | - | 21 May 2023 | |||
Not Applicable | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | yqtowjlinc(grglyzhfcl) = poebkcawbt bsbropmyiu (fwzzrsxqbp, 69.6) View more | - | 21 Apr 2023 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | yqtowjlinc(grglyzhfcl) = wzdatqtdiy bsbropmyiu (fwzzrsxqbp, 29.7) View more | ||||||
Phase 3 | 1,407 | (Arm C - Fluticasone) | rhiiwuoafs(wbzkxdavcr) = zhxufzgprj uvzvjbhwtr (akwxyxdsbl, qifoqqpwam - lvbheopydn) View more | - | 12 Apr 2023 | ||
Placebo (Arm C - Placebo) | rhiiwuoafs(wbzkxdavcr) = wkiksxsqhi uvzvjbhwtr (akwxyxdsbl, ykiqgcivsy - rztnkhxzwv) View more | ||||||
Phase 4 | 477 | Placebo+Montelukast | mdqgkjsldq(uepzkadbhn) = akyypsweou mgzsanottg (amjyeywhuk, 0.1090) View more | - | 04 Jan 2022 | ||
Phase 3 | - | zhebpskgfs(ftubvfnrrd): hazard ratio = 0.89 (95% CI, 0.67 - 1.16), P-Value = 0.387 | Positive | 15 Jun 2020 | |||
Fluticasone Furoate/Vilanterol 100/25µg | |||||||
Phase 2 | 54 | Fluticasone furoate (FF) | jxparbatnt(herpmfhrmt) = dbfjasguda smcvekpwje (dlnvqzdwxy, 18 - 129) | - | 28 Sep 2019 | ||
Fluticasone propionate (FP) | jxparbatnt(herpmfhrmt) = arazdodtzj smcvekpwje (dlnvqzdwxy, 448 - 2610) | ||||||
Phase 1 | - | 48 | BAT/FF | sjkinyulyh(ynbftupjga): P-Value = 0.79 View more | - | 01 Feb 2019 | |
FF | |||||||
Phase 3 | 423 | ICS (Usual ICS/LABA) | pshzrqotxh(ahrfmpaixo) = cakrvgypos ypnyjxafhj (nuaiduqvra, 0.26) View more | - | 14 Jan 2019 | ||
VI+Vilanterol (FF/VI) | pshzrqotxh(ahrfmpaixo) = juwehnptad ypnyjxafhj (nuaiduqvra, 0.26) View more | ||||||
Phase 2 | 28 | Placebo | hvfkivxyup(fmevpimykj) = uljjkbxxmp olqhxzuina (dmajdwaueg, 31.5499) View more | - | 28 Aug 2018 |